Drug Profile
Saroglitazar - Zydus Cadila
Alternative Names: [14C] saroglitazar; [14C]-Saroglitazar; Bilypsa; Lipaglyn; Saroglitazar Magnesium; Saroglitazar Mg; ZY-H1Latest Information Update: 08 Nov 2023
Price :
$50
*
At a glance
- Originator Zydus-Cadila
- Developer Zydus Cadila; Zydus Discovery DMCC
- Class Antihyperglycaemics; Antihyperlipidaemics; Carboxylic acids; Hepatoprotectants; Propionic acids; Pyrroles; Small molecules
- Mechanism of Action Peroxisome proliferator-activated receptor alpha agonists; Peroxisome proliferator-activated receptor gamma agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Dyslipidaemias; Hypertriglyceridaemia
- Registered Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis; Type 2 diabetes mellitus
- Phase III Lipodystrophy; Primary biliary cirrhosis
- Phase II Liver disorders; Polycystic ovary syndrome
Most Recent Events
- 06 Nov 2023 Lupin and Zydus Biosciences agree to co-promote Saroglitazar in India for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis
- 04 Nov 2022 Efficacy data from a phase II trial in Non-alcoholic fatty liver disease presented at the 73rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2022)
- 28 Sep 2022 No recent reports of development identified for phase-I development in Dyslipidaemias(In volunteers) in India (PO, Tablet)